# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic ...
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $10 pri...
RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.